Delving into the Latest Updates on Shijiazhuang Zhikang Hongren New Drug Development Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Other Diseases

Respiratory Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	3
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Small molecule drug	4

Top 5 Target	Count

FGFRs(Fibroblast growth factor receptors)	1
WEE1(Serine/threonine-protein kinase WEE1)	1
ATR(Serine-protein kinase ATR)	1

第一阶段（剂量递增阶段）：主要目的： -评估 SC0245 单药在晚期恶性实体瘤患者的安全性和耐受性； -确定 SC0245 的剂量限制毒性（Dose-Limiting Toxicity， DLT）和最大耐受剂量（MTD）或 II 期推荐剂量（RP2D）。次要目的： - 评估 SC0245 单药在晚期恶性实体瘤患者中的药代动力学（PK）特征； -评估 SC0245 单药在晚期恶性实体瘤患者中的初步抗肿瘤活性。第二阶段（剂量扩展阶段）主要目的：进一步评估 SC0245 单药在晚期恶性实体瘤患者的安全性和耐受性。次要目的： -进一步在多种特定肿瘤类型中初步评价 SC0245 单药在晚期恶性实体瘤患者中的抗肿瘤活性。 -进一步探索生物标记物与临床疗效之间的关系。

[Translation]

Phase I (Dose Escalation Phase): Primary Objectives: - To evaluate the safety and tolerability of SC0245 monotherapy in patients with advanced malignant solid tumors; - To determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) or Phase II recommended dose (RP2D) of SC0245. Secondary Objectives: - To evaluate the pharmacokinetic (PK) characteristics of SC0245 monotherapy in patients with advanced malignant solid tumors; - To evaluate the preliminary anti-tumor activity of SC0245 monotherapy in patients with advanced malignant solid tumors. Phase II (Dose Expansion Phase) Primary Objectives: To further evaluate the safety and tolerability of SC0245 monotherapy in patients with advanced malignant solid tumors. Secondary Objectives: - To further preliminarily evaluate the anti-tumor activity of SC0245 monotherapy in patients with advanced malignant solid tumors in multiple specific tumor types. - To further explore the relationship between biomarkers and clinical efficacy.

Start Date29 Jun 2021

Sponsor / Collaborator

Shijiazhuang Zhikang Hongren New Drug Development Co., Ltd.

CTR20210649

/ RecruitingPhase 1

一项开放、单臂的I期临床研究：评价SC0191片在晚期恶性实体瘤患者中的安全性、耐受性、药代动力学特征和药效动力学特征，并初步探索SC0191片的抗肿瘤活性

[Translation] An open, single-arm Phase I clinical study: To evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic characteristics of SC0191 tablets in patients with advanced malignant solid tumors, and to preliminarily explore the anti-tumor activity of SC0191 tablets

主要目的： - 评估SC0191片单药在晚期恶性实体瘤患者中的DLT发生情况（剂量爬坡期）； - 确定SC0191片单药的II期临床推荐剂量（RP2D）（剂量爬坡期）； - 评估SC0191片单药在晚期恶性实体瘤患者中的安全性和耐受性；次要目的： - 评估SC0191片单药在晚期恶性实体瘤患者中的药代动力学（PK）特征； - 评估SC0191片单药在晚期恶性实体瘤患者中的初步抗肿瘤活性。

[Translation]

Primary objectives: - To evaluate the occurrence of DLT of SC0191 tablets alone in patients with advanced malignant solid tumors (dose escalation phase); - To determine the recommended dose (RP2D) of SC0191 tablets alone in Phase II clinical trials (dose escalation phase); - To evaluate the safety and tolerability of SC0191 tablets alone in patients with advanced malignant solid tumors; Secondary objectives: - To evaluate the pharmacokinetic (PK) characteristics of SC0191 tablets alone in patients with advanced malignant solid tumors; - To evaluate the preliminary anti-tumor activity of SC0191 tablets alone in patients with advanced malignant solid tumors.

Start Date25 Jun 2021

Sponsor / Collaborator

Shijiazhuang Zhikang Hongren New Drug Development Co., Ltd.

CTR20210215

/ RecruitingPhase 1

一项多中心、开放、单臂、非随机的I 期临床试验：评估泛FGFR 抑制剂SC0011 片在晚期恶性实体瘤患者的安全性、耐受性、药代动力学及药效动力学特征，并初步探索SC0011 片的抗肿瘤活性

[Translation] A multicenter, open, single-arm, non-randomized Phase I clinical trial: To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the pan-FGFR inhibitor SC0011 tablets in patients with advanced malignant solid tumors, and to preliminarily explore the anti-tumor activity of SC0011 tablets

1、评价SC0011 片的安全性和耐受性； 2、确定SC0011 片的最大耐受剂量（MTD）和II 期推荐剂量（RP2D）； 3、评价SC0011 片的药代动力学（PK）特征； 4、评价SC0011 片的药效动力学（PD）特征； 5、初步评价SC0011 片的抗肿瘤活性； 6、初步评价在FGFR 基因检测异常受试者中SC0011 片的疗效。

[Translation]

1. Evaluate the safety and tolerability of SC0011 tablets; 2. Determine the maximum tolerated dose (MTD) and phase II recommended dose (RP2D) of SC0011 tablets; 3. Evaluate the pharmacokinetic (PK) characteristics of SC0011 tablets; 4. Evaluate the pharmacodynamic (PD) characteristics of SC0011 tablets; 5. Preliminary evaluation of the anti-tumor activity of SC0011 tablets; 6. Preliminary evaluation of the efficacy of SC0011 tablets in subjects with abnormal FGFR gene detection.

Start Date04 Mar 2021

Sponsor / Collaborator

Shijiazhuang Zhikang Hongren New Drug Development Co., Ltd.

100 Clinical Results associated with Shijiazhuang Zhikang Hongren New Drug Development Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Shijiazhuang Zhikang Hongren New Drug Development Co., Ltd.

Login to view more data

100 Deals associated with Shijiazhuang Zhikang Hongren New Drug Development Co., Ltd.

Login to view more data

100 Translational Medicine associated with Shijiazhuang Zhikang Hongren New Drug Development Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 16 Sep 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1

4

3

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

SC-0245 ( ATR )	Advanced Malignant Solid Neoplasm More	Phase 1
SC-0011 ( FGFRs )	Advanced Malignant Solid Neoplasm More	Phase 1
Sufenidone	Idiopathic Pulmonary Fibrosis More	Phase 1
SC-0191 ( WEE1 )	Advanced Malignant Solid Neoplasm More	Phase 1
WXSH0081	Inflammatory Bowel Diseases More	Discontinued